There are a number of parts of the legislation that would have helped in both those situations.
The first part is really what we talked about in terms of the recall. Again, for the vast majority of companies when Health Canada said they would like a recall, they do recall. The issue is if we don't get that consent, if they don't want to recall. Again, down to the patient level.... This gives us the authority to say they must recall. That's one part of it.
The other part of it really speaks to getting information around off-label use. Again, off-label use certainly is within the purview of practitioners. They need to be able to make decisions for their individual patients. What the legislation does is it gives Health Canada the authority to get information on off-label use.
If there is an off-label use out there that's potentially introducing risks, then we have the ability to ask a company to study it, to get information and then to use that information to make changes to the label or to communicate to people so that when they're actually making decisions about their health they are doing that with the benefit of all the information that they need.